This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Biosimilar Bevacizumab (Biocon)

Biocon, Ltd.

Drug Names(s): Biosimilar Avastin

Description: Biocon's compound is a biosimilar to the antibody drug Avastin.

The antibody inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF). Inhibiting VEGF protein function leads to diminished blood vessel formation such that tumors tend to be deprived of nourishing blood flow needed for their growth and metastasis. On the other hand, VEGF inhibition has been associated with adversities of both clotting and bleeding related to its actions at the level of blood vessel channel-lining cells.

Biosimilar Bevacizumab (Biocon) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug